MTEM vs. AMGN, GILD, VRTX, REGN, ALNY, BIIB, UTHR, NBIX, INCY, and BMRN
Should you be buying Molecular Templates stock or one of its competitors? The main competitors of Molecular Templates include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry.
Molecular Templates vs.
Molecular Templates (NASDAQ:MTEM) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, community ranking, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.
Amgen has a consensus target price of $314.91, suggesting a potential upside of 14.59%. Given Amgen's stronger consensus rating and higher probable upside, analysts clearly believe Amgen is more favorable than Molecular Templates.
In the previous week, Amgen had 64 more articles in the media than Molecular Templates. MarketBeat recorded 64 mentions for Amgen and 0 mentions for Molecular Templates. Amgen's average media sentiment score of 1.20 beat Molecular Templates' score of 0.00 indicating that Amgen is being referred to more favorably in the news media.
Amgen has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Amgen has a net margin of 13.00% compared to Molecular Templates' net margin of -61.35%. Amgen's return on equity of 168.35% beat Molecular Templates' return on equity.
Molecular Templates has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.
95.5% of Molecular Templates shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 13.9% of Molecular Templates shares are held by company insiders. Comparatively, 0.7% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Amgen received 1206 more outperform votes than Molecular Templates when rated by MarketBeat users. Likewise, 72.07% of users gave Amgen an outperform vote while only 67.32% of users gave Molecular Templates an outperform vote.
Summary
Amgen beats Molecular Templates on 16 of the 19 factors compared between the two stocks.
Get Molecular Templates News Delivered to You Automatically
Sign up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Molecular Templates Competitors List
Related Companies and Tools
This page (NASDAQ:MTEM) was last updated on 1/21/2025 by MarketBeat.com Staff
Free MTEM Stock Alerts